All Stories

Incyte's mixed Opzelura data in prurigo nodularis add uncertainty to potential approval bid: analysts

Incyte's Opzelura was successful in just one of two parallel phase 3 trials assessing the JAK inhibitor in the skin condition prurigo nodularis.

Mar 10, 2025 - 16:30
 0
Incyte's mixed Opzelura data in prurigo nodularis add uncertainty to potential approval bid: analysts
Incyte's Opzelura was successful in just one of two parallel phase 3 trials assessing the JAK inhibitor in the skin condition prurigo nodularis.
Read More

Tags:

Previous Article

The Biggest Disadvantages Of All-Season Tires

Next Article

GSK, Novartis, Lilly among Big Pharmas celebrating International Women’s Day 2025

Related Posts

FDA approves Ono's rare tumor drug from $2.4B Deciphera buyout

FDA approves Ono's rare tumor drug from $2.4B Deciphera...

Feb 15, 2025  0

As Gardasil underwhelms, Merck lights up landmarks in China in HPV awareness day push

As Gardasil underwhelms, Merck lights up landmarks in C...

Mar 4, 2025  0

With plan to build 4 new plants, Eli Lilly doubles down on US drug manufacturing

With plan to build 4 new plants, Eli Lilly doubles down...

Feb 26, 2025  0